Page last updated: 2024-09-04

jte 522 and Cancer of Prostate

jte 522 has been researched along with Cancer of Prostate in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kamoi, K; Kawauchi, A; Miki, T; Mizutani, Y; Ukimura, O1

Other Studies

1 other study(ies) available for jte 522 and Cancer of Prostate

ArticleYear
Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer.
    The Journal of urology, 2002, Volume: 168, Issue:6

    Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzenesulfonates; Blotting, Western; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Fluorouracil; Humans; Isoenzymes; Male; Membrane Proteins; Oxazoles; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Urinary Bladder Neoplasms

2002